Oppenheimer reiterated their outperform rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $410.00 target price on the pharmaceutical company’s stock. Other research analysts also recently issued research reports about the stock. William Blair began coverage on shares of Vertex Pharmaceuticals […]
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Equities researchers at William Blair lowered their FY2024 earnings per share (EPS) estimates for Vertex Pharmaceuticals in a research report issued on Thursday, July 20th. William Blair analyst M. Minter now anticipates that the pharmaceutical company will post earnings per share of $14.40 for the year, down […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Morgan Stanley from $305.00 to $340.00 in a report released on Monday, FlyOnTheWall reports. A number of other analysts have also issued reports on the stock. Stifel Nicolaus boosted their price target on shares of Vertex Pharmaceuticals from $300.00 to $340.00 in a […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday. A number of other equities research analysts also recently issued reports on the company. Maxim Group increased their price objective on Vertex Pharmaceuticals from $325.00 to […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by equities research analysts at Morgan Stanley from $305.00 to $340.00 in a research note issued to investors on Monday, The Fly reports. Morgan Stanley’s price target points to a potential downside of 3.38% from the company’s current price. A number of other brokerages […]